160 related articles for article (PubMed ID: 9859690)
1. [Mechanism of action of zolmitriptan].
Pascual J
Neurologia; 1998 Oct; 13 Suppl 2():9-15. PubMed ID: 9859690
[TBL] [Abstract][Full Text] [Related]
2. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Hoskin KL; Goadsby PJ
Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
4. [Clinical efficacy of zolmitriptan in migraine].
Leira R; Noya M
Neurologia; 1998 Oct; 13 Suppl 2():16-24. PubMed ID: 9859691
[TBL] [Abstract][Full Text] [Related]
5. Zolmitriptan.
Can Fam Physician; 1999 Jun; 45():1491-4, 1497-501. PubMed ID: 10386213
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
7. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR
Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508
[TBL] [Abstract][Full Text] [Related]
8. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats.
Cumberbatch MJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1998 Nov; 362(1):43-6. PubMed ID: 9865528
[TBL] [Abstract][Full Text] [Related]
9. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
10. Zolmitriptan for migraine.
Med Lett Drugs Ther; 1998 Feb; 40(1021):27-8. PubMed ID: 9505961
[No Abstract] [Full Text] [Related]
11. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan.
Peterlin BL; Rapoport AM
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):899-911. PubMed ID: 18028032
[TBL] [Abstract][Full Text] [Related]
13. [Safety profile of 311C90 (zolmitriptan)].
Morales Asín F
Neurologia; 1998 Oct; 13 Suppl 2():25-30. PubMed ID: 9859692
[TBL] [Abstract][Full Text] [Related]
14. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of migraine--new insights.
Hargreaves RJ; Shepheard SL
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S12-9. PubMed ID: 10563228
[TBL] [Abstract][Full Text] [Related]
16. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
Gawel M; Aschoff J; May A; Charlesworth BR;
Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
[TBL] [Abstract][Full Text] [Related]
17. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy.
Goadsby PJ; Yates R
Headache; 2006 Jan; 46(1):138-49. PubMed ID: 16412161
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?
Goadsby PJ; Hoskin KL
Pain; 1996 Oct; 67(2-3):355-9. PubMed ID: 8951929
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Deleu D; Hanssens Y
J Clin Pharmacol; 2000 Jul; 40(7):687-700. PubMed ID: 10883409
[TBL] [Abstract][Full Text] [Related]
20. Almotriptan and zolmitriptan in the acute treatment of migraine.
Goadsby PJ; Massiou H; Pascual J; Diener HC; Dahlöf CG; Mateos V; Dowson AJ; Raets I; Cunha L; Färkkilä M; Manzoni GC
Acta Neurol Scand; 2007 Jan; 115(1):34-40. PubMed ID: 17156263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
